Med Lic, Chief Executive Officer
Jakob Lindberg was appointed as CEO in 2011.
In addition to being CEO of Oncopeptides, Jakob is a Venture Partner at Patricia Industries, part of the Investor AB group of companies.
Jakob’s previous roles include being an analyst for Merrill Lynch & Co and a consultant at McKinsey&Co. Jakob also co-founded Cellectricon, a provider of cell-based screening services to accelerate drug discovery, where he also served as CEO.
Jakob studied medicine at the Karolinska Institute where he also gained a Med Lic in Molecular Immunology and an MSc in pre-clinical medicine. He also has a BA in Finance and Administration from Stockholm University.
Holdings in Oncopeptides: 235 409 shares (220,109 directly owned, 15,300 indirectly owned through Lindberg Life-Science AB), 1,070 employee options* and 204,190 options**.
Other current positions: Director of Affibody Medical AB, Atlas Antibodies AB and Lindberg Life-Science AB. Alternate Director of Oncopeptides Incentive AB. CEO of Lindberg Life-Science AB.
MSc, Chief Financial Officer
Anders Martin-Löf was appointed CFO in 2018.
Anders was previously CFO of Wilson Therapeutics AB and RaySearch Laboratories AB, both listed on Nasdaq Stockholm. He held various business development positions for Swedish Orphan Biovitrum where he also served as Director of Investor Relations. In addition he has worked as a management consultant at the Boston Consulting Group, Cell Network and as co-founder and CEO of ScienceCap.
Anders holds an MSc in Engineering Physics from the Royal Institute of Technology, and a BA in Business Administration and Economics, from Stockholm University.
Holdings in Oncopeptides: 3,000 shares and 200,000 options**.
Other current positions: Director of Cantargia AB and alternate director of Lisa Martin-Löf konsultbyrå AB.
Dr Med Sci, MSc Pharm, Head of Medical Relations
Bengt Gustavsson was appointed Head of Medical Relations 2017.
In addition to his role as Head of Medical Relations at Oncopeptides, Bengt also runs his own consultancy company Sangus Jazz AB.
Previous positions Bengt has held include Nordic Medical Director at Celgene AB and at Novartis Oncology, and Nordic Clinical Research Director at Sanofi-Aventis.
Bengt Gustavsson holds a Master of Science in Pharmacy and is Doctor of Medical Science (Pathology) from Uppsala University. He also holds an EUCOR/ECPM-exam in Pharmaceutical Medicine from the EUCOR-universities in Basel, Freiburg and Strasbourg.
Holdings in Oncopeptides: 600 shares and 102,595 options**.
Other current positions: Chairman and CEO of Sangus Jazz AB. Board Director of NanexaAB, adviser to Scandinavian CRO AB.
MD, MSc, EVP Clinical Strategy and Chief Scientific Officer
Christian Jacques was appointed EVP Clinical Strategy and Chief Scientific Officer in 2018.
In addition to being EVP Clinical Strategy and CSO of Oncopeptides, Christian is Chief Scientific Officer at Pharma Biotech Consultants LLC, which provides consulting services to companies within the area of hemato-oncology.
Christian has previously held roles at a number of life sciences companies including as Vice President Clinical Development at Celgene, where he was in charge of the multiple myeloma clinical development for Celgene products and got approval of pomalidomide (Pomalyst or Imnovid) in the US, EU and several other key countries. He also led the global clinical development for Revlimid. Christian also held roles at Novartis, Johnson & Johnson, Aventis (Formerly Rhone-Poulenc) and Pierre Fabre Oncologie, all within Oncology.
He has more than 54 publications in peer-reviewed journals or at major congresses.
Christian holds an MD degree and Internal Medicine degree from Université Catholique de Louvain, Belgium. Christian has been a hospital practitioner for 10 years.
Holdings in Oncopeptides: 200,000 options**
Other current positions: Dr Jacques is a member of American Society of Clinical Oncology (ASCO) and American Society of Hematology (ASH).
MSc, Head of Regulatory Affairs
Elisabeth Augustsson was appointed as Head of Regulatory Affairs in 2015.
In addition to being Head of Regulatory Affairs of Oncopeptides, Elisabeth is the President and Founder of Restracom, which provides consulting services to pharmaceutical companies in the area of regulatory strategies and communication with regulatory authorities.
Elisabeth has previously held roles at a number of life sciences companies including Pharmacia&Upjohn, Medivir AB, Biovitrum AB, Karo Bio AB and Alexion AB.
Elisabeth holds an MSc Pharm from Uppsala University.
Holdings in Oncopeptides: 72,117 options**.
Other current positions: Chairman of the Board and CEO of Restracom AB.
MSc Pharm, Vice President, Head of Clinical Development
Eva Nordström was appointed as Head of Clinical Development in 2012.
Previous positions Eva has held include Global Product Director and Vice President roles at Pharmacia and AstraZeneca based both in Sweden and the USA. She has led international cross-functional teams through all phases of drug development, including phase III and product launches. Eva has been responsible for individual project strategies including their implementation as well as disease area strategies, portfolio management and in-licensing.
Eva holds an MSc Pharm from Uppsala University and an Executive MBA from Stockholm School of Economics.
Holdings in Oncopeptides: 150,200 shares, 33 employee options* and 102,595 options**.
Other current positions: Alternate Director of Utilica AB.
PhD, Head of Research and CMC (Chemistry, Manufacturing & Control)
Fredrik Lehmann was appointed Head of CMC in 2010 and Head of Research in 2018.
In addition to being Head of CMC for Oncopeptides, Fredrik is an independent consultant within preclinical research and CMC.
Fredrik has previously held positions at a number of life sciences businesses including Pharmacia, Personal Chemistry, Biovitrum and Recipharm. He has also co-founded six life science companies.
Fredrik holds a PhD in medicinal chemistry from Gothenburg University.
Holdings in Oncopeptides: 1,000 shares (indirectly owned through OT Lehmann Holding AB), 50 employee options* and 72,117 options**.
Other current positions: Director and CEO of OT Pharmaceuticals AB. Board member of OT Lehmann Holding AB and Chariman of the board of Synartro AB.
MD, PhD, Associate Prof, Chief Medical Officer
Johan Harmenberg was appointed as the Chief Medical Officer in 2012.
Johan has previously held roles at a number of life sciences companies including as CEO for Axelar AB and Akinion AB, Chief Medical Officer at Algeta AB, Vice President Development for Medivir AB and Global Medical Director for Pharmacia Upjohn. He is the author of over 100 publications for a range of scientific journals.
Johan holds a PhD and MD from the Karolinska Institute in Stockholm, Sweden. He is also Associate Professor (Docent) at the same institution.
Holdings in Oncopeptides: 5,000 shares, 160 employee options* and 72,117 options**.
Other current positions: Chairman of Gungner Medical AB, KarSar Fastigheter AB and Sarak Fastigheter AB.
Chief Commercial Officer
Paula Boultbee was appointed as the Chief Commercial Officer in 2016.
Paula comes with expertise that is acquired from both small and large pharmaceutical companies, most recently she was the Executive Vice President of Sales and Marketing at Pharmacyclics where she did build a team and launched their first commercial product, Imbruvica that has become a multi-billion dollar asset. She has also held positions at Novartis, Amgen and Pharmacia with growing responsibility in both sales, brand management, country and regional leadership roles; Novartis as Executive Director a leader and executer for a global launch of flagship product Glivec/Gleevec (imatinib) with $6Billon global sales.
Before joining Oncopeptides she worked as independent consult and has supported several companies in building their commercial markets that have led to successful launch, fundraising, desired acquisitions and licensing agreements.
Paula has nursing degree.
Holdings in Oncopeptides: 102,595 options**.
Other current positions: Chairman of The Max Foundation and Isofol Medical AB board member. Advisor to Monocl AB and early stage biotech companies in the Bay Area California. Paula runs PTB Consulting LLC.
BSc, Head of Investor Relations
Rein Piir was appointed as Investor Relations Manager in 2016.
In addition to his role as Investor Relations Manager at Oncopeptides, Rein holds investor relations position at the life sciences company Camurus AB.
Previous roles Rein has held include Head of Strategy at Alecta AB and Head of Analysis at Carnegie Investment Bank AB as well as Chief Financial Officer and Head of Investor Relations at Medivir AB. Rein also worked for several years at the international account anting firm PricewaterhouseCoopers. Rein currently holds directorship at the Swedish life sciences company Integrative Research Laboratories Sweden.
Rein Piir holds a B.Sc. Business Economics and Management from Uppsala University, Sweden.
Holdings in Oncopeptides: 2,500 shares (Indirectly owned through Piir & Partner AB) and 72,117 options**.
Other current positions: Chairman and CEO of Piir & Partner AB. Board member of Integrative Research Laboratories Sweden AB and L. E. Svensson Snickeri AB.
MD, PhD, Head of Pharmacovigilance
Thomas Bradley was appointed as Head of Pharmacovigilance in 2018.
IIn addition to being Head of Pharmacovigilance of Oncopeptides, Thomas is an independent consultant in the area of pharmacovigilance and drug safety.
Thomas has previously held roles in pharmacovigilance and drug safety at Medical Product Agency and at a number of life sciences companies including Pharmacia & Upjohn, Parke-Davis, Pfizer, Inc., MedImmune Vaccines, Inc. and Telik, Inc.
Thomas holds a PhD and MD from the Karolinska Institute in Stockholm, Sweden.
Holdings in Oncopeptides: 51,595 options**.
Other current positions: Member of “Board of Directors (Governing Board) of the foundation WHO Collaborating Centre for International Drug Monitoring”, Board member of the NEPI (Network for pharmacoepidemiology) Foundation, Director of Bradley Konsult AB. Consultant at Karolinska University Hospital.
* Each employee option entitles the holder to acquire 900 shares per option in the company.
** The options entitles to one share per option in accordance with existing terms.
For more information and terms please read under Corporate Governance – Remuneration.
Holdings in Oncopeptides AB as of November 12, 2018.